-+ 0.00%
-+ 0.00%
-+ 0.00%

Rhelion subsidiary Filament Health ships PEX010 psilocybin to University of Calgary for Phase 2 PTSD trial

PUBT·09/29/2026 11:53:49
Listen to the news
Rhelion subsidiary Filament Health ships PEX010 psilocybin to University of Calgary for Phase 2 PTSD trial
  • Rhelion’s wholly owned unit Filament Health shipped PEX010 to the University of Calgary for a Phase 2 PTSD trial.
  • The PsiPTSD study targets adult survivors of intimate partner violence; the university sponsors the trial.
  • Filament develops and supplies PEX010, a GMP botanical psilocybin candidate used across more than 80 research studies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhelion Life Sciences Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202609290753NEWSFILECNPR____20260929_316514_1) on September 29, 2026, and is solely responsible for the information contained therein.